OASIS PHARMACEUTICALS, LLC
Oasis Pharmaceuticals - GPCRs - Pepducin Technology - PAR2
LEXINGTON, United States · Founded 2015 · $1.8M raised
- Headquarters
- LEXINGTON, Massachusetts
- Employees
- 1–10
- Founded
- 2015
- Business Model
- B2B
- Website
- pepducin.com
- Total Funding
- $1.8M
- Last Round
- $1000K GrantJan 2024
About
Oasis Pharmaceuticals is a clinical-stage biotech startup advancing Pepducin technology, which targets the intracellular surface of G-protein coupled receptors (GPCRs) including PAR2. The company is developing treatments for inflammatory, fibrotic, and metabolic disorders including MASH, IPF, and atopic dermatitis in collaboration with Tufts Medical Center.
Summary
OASIS PHARMACEUTICALS, LLC is a Biotech company based in LEXINGTON, United States, founded in 2015. It has raised $1.8M in total, most recently a $1000K Grant round in Jan 2024.
Tech & App Stack
3 technologies & apps tracked
Create a free account — 25 credits a month to unlock the full tech & app stack, funding history, and valuations.
Funding History
No funding data available yet.
Know something? Help us improve our data.
Similar Companies
China's leading blood products manufacturer
Global contract research organization providing comprehensive drug development and laboratory ser...

Global fertility clinics platform

Specialty pharmaceutical company
Biopharmaceutical services company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.